Bronwen E Shaw, MD, PhD

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MD - Doctor of Medicine
PhD

Biography

Dr. Shaw received her MD (MBChB) from the University of Cape Town, South Africa in 1993. All of her subsequent postgraduate haematology specialist training was completed in London, UK where she also received her PhD in Clinical Sciences and Immunology from University College London in 2004. Her PhD was entitled Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors.

Research Interests

Prior to taking up her position at the CIBMTR and MCW, Dr. Shaw was a Consultant Haematologist specializing in Stem Cell Transplantation and Survivorship issues at the Royal Marsden Hospital in Sutton, UK. She simultaneously held the position of Chief Medical Officer at Anthony Nolan, the UK’s national unrelated donor registry. In this position she had oversight of the donor research activities and the medical operations of the organization. She also held a senior scientific role, with direct supervision of several PhD and MD students working in the area of immunogenetics, donor selection, and the donor experience.

Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

(Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, Szwajcer D, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, Yared JA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, Hashem H, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, Shaw BE, Khera N, Wood WA, Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W.) Cancer. 2021 Feb 15;127(4):609-618 PMID: 33085090 PMCID: PMC7855526 SCOPUS ID: 2-s2.0-85092920705 10/22/2020
Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis.

(Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR.) Bone Marrow Transplant. 2021 Feb;56(2):522 PMID: 32514157 PMCID: PMC7722110 SCOPUS ID: 2-s2.0-85086026026 06/10/2020
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.

(Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL.) Lancet Haematol. 2021 Jan 19 PMID: 33482113 PMCID: PMC7816949 01/23/2021
Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study.

(Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA.) Biol Blood Marrow Transplant. 2020 12;26(12):2365-2371 PMID: 32829080 PMCID: PMC7686016 SCOPUS ID: 2-s2.0-85091208680 08/24/2020
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.

(Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee.) Biol Blood Marrow Transplant. 2020 12;26(12):2181-2189 PMID: 32717432 PMCID: PMC7380217 SCOPUS ID: 2-s2.0-85089451061 07/28/2020
Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis.

(Dehn J, Chitphakdithai P, Shaw BE, McDonald AA, Devine SM, Burns LJ, Spellman S.) Biol Blood Marrow Transplant. 2020 Oct 10 PMID: 33045385 SCOPUS ID: 2-s2.0-85095990503 10/13/2020
Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.

(Farhadfar N, Burns LJ, Mupfudze T, Shaw BE, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ.) Biol Blood Marrow Transplant. 2020 Oct 09 PMID: 33045387 PMCID: PMC7546661 SCOPUS ID: 2-s2.0-85096828571 10/13/2020
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 10;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score.

(Berro M, Chhabra S, Piñana JL, Arbelbide J, Rivas MM, Basquiera AL, Vitriu A, Requejo A, Milovic V, Yantorno S, Bentolila G, Garcia JJ, Castro M, Palmer S, Saslavsky M, Duarte P, Cerutti A, Jarchum G, Tisi Baña M, Thapa B, Solano C, Sureda A, Rovira M, Shaw BE, Kusminsky G, Grupo Argentino de Trasplante de Médula Ósea y Terapia Celular (GATMO-TC).) Biol Blood Marrow Transplant. 2020 10;26(10):1828-1832 PMID: 32640312 SCOPUS ID: 2-s2.0-85088997993 07/09/2020
Letter to the Editor Regarding Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE.) Biol Blood Marrow Transplant. 2020 09;26(9):e241-e242 PMID: 32589922 PMCID: PMC7309826 SCOPUS ID: 2-s2.0-85087728830 06/27/2020
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.

(D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM.) Biol Blood Marrow Transplant. 2020 08;26(8):e177-e182 PMID: 32438042 PMCID: PMC7404814 SCOPUS ID: 2-s2.0-85085969206 05/22/2020
Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening.

(Nacheva E, Ahyee T, Addada J, Navarette C, Pamphilon D, Regan F, Pawson R, Szydlo R, Goldman J, Mackinnon S, Shaw BE, Madrigal A.) Bone Marrow Transplant. 2020 07;55(7):1290-1296 PMID: 32440014 SCOPUS ID: 2-s2.0-85085313993 05/23/2020